Objective: To investigate expression of centrosomal protein (Cep55) and forkhead transcription factor (FoxM1) in cervical cancer tissue, and to analyze its correlation with clinicopathological features and prognosis. Methods: The clinical data and the follow-up data of 124 patients with cervical cancer admitted to our hospital from January 2010 to April 2013 were retrospectively analyzed. The Cep55 and FoxM1 protein expression in the cancer tissues (study group, n=124) and adjacent normal tissues (control group, n=124) were detected. Then the relationships between expression levels and clinicopathological features and prognosis were analyzed. Results: (1) The positive expression rates of Cep55 and FoxM1 protein in cervical cancer tissues were 75.00% (93/124) and 77.42% (96/124) respectively (P<0.05). (2) The expression of Cep55 and FoxM1 were not correlated with age, pathological type and vaginal involvement of cervical cancer patients (P>0.05), while related with the lymph node metastasis, FIGO stage, differentiation degree and depth of myometrial invasion in cervical cancer patients (P<0.05).(3) Univariate analysis showed that the survival time of patients with FIGOII stage, poor differentiation, myometrial invasion depth ≥ 1/2 and positive Cep55 and FoxM1 protein were significantly shorter (P<0.05). (4) The multivariate Cox proportional hazards regression model showed that FIGO II stage, poor differentiation, depth of myometrial invasion ≥ 1/2, and positive Cep55 and FoxM1 protein were independent risk factors for the prognosis of patients with cervical cancer (P<0.05). Conclusion: Cep55 and FoxM1 proteins are expressed at high levels in cervical cancerous tissues, which are even higher among patients with FIGO II stage, poor differentiation, and myometrial invasion depth ≥ 1/2, since these factors are independent risk factors for the prognosis of patients with cervical cancer. |
[1] 范淑英,李春晓,林锋,等.宫颈癌中转移相关基因MTA1高表达的临床意义及其协同表达基因的生物信息学分析[J].解放军医学杂志,2016,41(5):363-367.
[2] 蒋奉希,张力忆,桂定清.ⅠB2-ⅡB期宫颈癌新辅助化疗效果及敏感性影响因素分析[J].临床误诊误治,2017,30(10):94-97.
[3] 赵凯旋,徐静云,卢春.人乳头瘤病毒E6蛋白通过上调氯离子蛋白通道5的表达促进宫颈癌细胞迁移[J].江苏大学学报(医学版),2018,25(2):124-126.
[4] YIN Y,CAI J,MENG F,et al.MiR-144 suppresses proliferation,invasion,and migration of breast cancer cells through inhibiting CEP55[J].Cancer Biol Ther,2018,19(4):306-315.
[5] 吕贇,聂少麟,胡英斌,等.FoxM1在结直肠癌中的表达及其临床意义[J].现代肿瘤医学,2016,24(13):2112-2115.
[6] 方三高,石群立,周晓军,等.解读2014年WHO女性生殖器官肿瘤分类(宫颈)[J].重庆医学,2015,43(28):3889-3899.
[7] 林仲秋,王丽娟,刘龙阳.国际妇产科联盟2012宫颈癌诊治指南解读[J].中国实用妇科与产科杂志,2013,9(5):323-325.
[8] QUAN M,CUI J,XIA T,et al.Merlin/NF2 suppresses pancreatic tumor growth and metastasis by attenuating the FOXM1-mediated Wnt/beta-catenin signaling[J].Cancer Res,2016,75(22):4778-4789.
[9] 邓亚勤,周新欢,姜李乐,等.σ1受体在子宫颈癌组织中高表达的意义及其配体化合物对子宫颈癌细胞生长的作用[J].中华妇产科杂志,2017,52(7):85-87.
[10] 迪拉热·力迪甫,努尔满古力·肉孜,热孜亚·肉孜阿洪,等.宫颈癌发生与ApoE、CLU和RelB表达调控的关系及意义[J].医学分子生物学杂志,2016,13(3):143-148.
[11] 马宗丽,沙红兰,朱东兵,等.葡萄糖转运蛋白-1、缺氧诱导因子-1α在宫颈上皮癌变过程中的表达及意义[J].中国临床研究,2016,29(12):1675-1677.
[12] 孙志超,李红霞,张智弘.乳腺癌组织中FoxM1和HIF-1α蛋白的表达及其与临床病理学指标的关系[J].江苏医药,2016,42(3):283-286.
[13] 周炳娟,马秋双,孙吉瑞,等.乳腺癌组织中FOXM1和PLK1的表达及意义[J].肿瘤防治研究,2017,44(3):193-196.
[14] 贺东黎.姜黄素通过ATK/FoxM1信号通路调控胃癌干细胞增殖及凋亡[J].中国组织工程研究,2016,20(32):4731-4737.
[15] 杨建敏,胡静文.Foxm1蛋白在人宫颈癌组织中的表达及与病理类型、分级、分期之间的关系[J].广东医学,2016,37(14):2150-2154.
[16] 张艳,乔炜超,孙影,等.FoxM1和ADAM17在乳腺癌中的表达及其临床意义[J].中国医药导报,2016,13(20):92-95.
[17] 马秋双,周炳娟,张金库,等.FoxM1、Cep55和c-Myc蛋白在基底细胞样乳腺癌中的表达及临床意义[J].河北医药,2015,43(1):5-9.
[18] 盖领,茅国新,赵铃铃,等.FOXM1在人乳腺癌组织和MCF-7细胞中的表达及临床意义[J].基础医学与临床,2015,35(8):1100-1105.
[19] 张义,叶小娟,高勇.FOXM1与肿瘤代谢关系的研究进展[J].中国肿瘤临床,2015,42(22):1108-1111.
[20] 郭丽梅,戴守勇.宫颈癌组织FoxM1蛋白的表达特点及其与病理学特征、预后的相关性[J].癌症进展,2018,16(5):134-136. |
